Bioexcelife
A Clinical Evaluation Report may look complete.
It may have literature, PMS data, device details, and a benefit-risk conclusion.
But still, a Notified Body may raise questions.
Why?
Because under EU MDR, a CER is not judged by its length. It is judged by the strength of its clinical logic.
A good CER does not just collect information. It connects evidence, claims, risks, PMS data, and conclusions into one clear story. If that story is weak, Notified Bodies will find the gaps quickly.
The New Reality Under EU MDR
Under EU MDR, Notified Bodies expect manufacturers to prove that the device is safe, performs as intended, and has an acceptable benefit-risk profile.
This means the CER must do more than describe the device. It must justify every clinical claim with reliable evidence.
Many CERs fail because they are written like summaries instead of scientific evaluations. They include data, but they do not explain why that data is enough.
That is where nonconformities begin.
Weak Clinical Evidence Is a Major Red Flag
One of the most common issues is weak or poorly linked clinical evidence.
A manufacturer may claim that the device improves performance, reduces complications, or provides clinical benefit. However, the CER may not include strong evidence to support those claims.
Sometimes the evidence is too general. Sometimes it belongs to a similar device. Sometimes it does not match the exact intended purpose.
Notified Bodies want to see clear traceability between the claim and the evidence. If the claim is strong, the evidence must be strong too.
Equivalence Claims Are Often Challenged
Equivalence is another area where many CERs face objections.
Under EU MDR, claiming equivalence is not easy. A manufacturer must show that the device is equivalent from a technical, biological, and clinical point of view.
It is not enough to say that two devices are similar.
The CER must clearly explain why the differences do not affect safety or performance. It must also show access to sufficient data for the equivalent device.
If equivalence is weak, the entire clinical evaluation can become weak.
State of the Art Is Not Just Background
Many CERs treat the State of the Art section as a basic literature overview.
That is a mistake.
The State of the Art sets the benchmark for what is acceptable in current clinical practice. It helps define expected benefits, known risks, alternative treatments, and performance standards.
If this section is outdated or too generic, the benefit-risk conclusion becomes harder to defend.
Notified Bodies want to see that the manufacturer understands the current clinical landscape and can show where the device fits within it.
PMS and PMCF Must Tell a Real-World Story
Under EU MDR, the CER is not a one-time document. It must stay connected to real-world data.
This is why PMS and PMCF are so important.
Notified Bodies often raise nonconformities when PMS data is only mentioned briefly or copied into the CER without proper analysis.
They want to see how post-market data supports continued safety and performance. They also want to know whether complaints, incidents, trends, or user feedback have changed the clinical conclusion.
If PMCF is not planned, the justification must be strong. A simple statement saying “PMCF is not required” is usually not enough.
Risk Management and CER Must Match
A CER cannot stand alone.
It must align with the risk management file.
If the risk file identifies certain clinical hazards, the CER should discuss them. If residual risks remain, the CER should help justify why they are acceptable.
A common nonconformity appears when the CER says the device is safe, but the risk file shows unresolved or poorly supported risks.
That kind of mismatch creates doubt.
Notified Bodies expect the clinical evaluation to support the overall benefit-risk profile of the device.
Generic Conclusions Create Weak Reports
The final conclusion of the CER is one of the most important sections.
Yet many reports end with generic wording such as:
“The device is safe and performs as intended.”
That is not enough.
The conclusion should clearly explain how the evidence supports safety, performance, clinical benefit, and acceptability of residual risks.
A strong conclusion feels earned. It is based on the full evaluation, not copied from a template.
Inconsistency Across Documents Can Trigger Questions
Notified Bodies do not review the CER in isolation.
They compare it with the IFU, labeling, risk management file, PMS plan, PMCF plan, GSPR checklist, and technical documentation.
If the intended purpose differs between documents, it raises concern. If the claims in the IFU are broader than the evidence in the CER, it creates a gap. If the GSPR checklist says clinical evidence supports compliance, the CER must clearly show that support.
Small inconsistencies can become major review questions.
How Manufacturers Can Avoid CER Nonconformities
The best way to avoid CER nonconformities is to prepare the report like a reviewer will challenge every statement.
Every claim should have evidence. Every risk should be addressed. Every conclusion should be traceable.
The CER should not feel like a collection of separate sections. It should feel like one connected clinical argument.
Before submission, manufacturers should ask:
Does the evidence truly support the intended purpose?
Are clinical claims justified?
Is the State of the Art current?
Are PMS and PMCF properly integrated?
Does the CER match the risk file and IFU?
If any answer is unclear, the CER needs improvement before Notified Body review.
Most CER nonconformities do not happen because manufacturers have no data.
They happen because the data is not properly connected, justified, or aligned.
Under EU MDR, a CER must be clear, evidence-based, traceable, and defensible.
A strong CER builds confidence. A weak CER creates questions.
And in Notified Body review, questions often mean delays.
How Bioexcel Can Help
At Bioexcel, we help medical device manufacturers strengthen their Clinical Evaluation Reports before submission.
Our team supports CER writing, gap assessment, equivalence justification, PMS and PMCF alignment, risk management linkage, and Notified Body query response.
We help ensure your CER is not just complete, but review-ready.
Need support with CER nonconformities or Notified Body questions? Partner with Bioexcel for a stronger and smoother clinical evaluation strategy.
